Takeda plots ‘unprecedented patient diversity’ for psoriasis drug that could compete with BMS

Japanese drugmaker Takeda Pharmaceuticals, for example, has set a lofty goal of achieving “unprecedented patient diversity” in phase 3 trials for a key psoriasis candidate, according to Karen Correa, vice president and head global clinical operations at Takeda.

The company’s TAK-279 is enrolling participants in a phase 3 trial with the ultimate goal of participants matching real-world data and the overall patient population.